Mp27-19 Rezūm Water Vapor Therapy for Large Volume (≥80 Ml) Benign Prostatic Enlargement: Large, Multi-Center Real-World Cohort

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology II (MP27)1 May 2024MP27-19 REZŪM WATER VAPOR THERAPY FOR LARGE VOLUME (≥80 ML) BENIGN PROSTATIC ENLARGEMENT: LARGE, MULTI-CENTER REAL-WORLD COHORT Roseanne Ferreira, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, and Dean Elterman Roseanne FerreiraRoseanne Ferreira , Naeem BhojaniNaeem Bhojani , Bilal ChughtaiBilal Chughtai , Kevin C. ZornKevin C. Zorn , and Dean EltermanDean Elterman View All Author Informationhttps://doi.org/10.1097/01.JU.0001009400.86696.a2.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Open or laser prostatectomy are the standard treatments for benign prostatic hyperplasia (BPH) of large volume prostates ≥80 ml. Rezūm is a minimally invasive procedure to ablate benign prostatic tissue. Herein, we report the prospective, multi-center results of the largest cohort of prostates ≥80 mL treated with Rezūm. METHODS: A prospective registry was established for Rezūm therapy in Canada (2019) at two high-volume centers. We reviewed data for patients followed between April 2019 and June 2023. All patients had baseline medical and BPH history documented along with uroflowmetry (Qmax and PVR), and validated questionnaires (IPSS, IPSS QoL, BPHII, IIEF-15, MSHQ-EjD function and bother). RESULTS: 175 patients (mean age 68.8±8.3 years) with prostate size ≥80 ml were treated with Rezūm. The median prostate volume was 105 ml (range 80-271 ml), 11.4% had prostate volume >150 ml and 79.4% had a median lobe. A prior history of urinary retention was documented in 54 patients. The procedure involved an average of 14±3.6 injections and median duration was 5 minutes (ranging from 2 to 13 minutes). Post-procedure catheterization was required for a mean duration of 14.3±7.7 days. IPSS reduced from a baseline score of 21.8 to 9.1, 9.3, 10.1 at 3, 12 and 24 months respectively. IPSS QoL score improved from a baseline of 4.5 to 1.5 at 12 months and 1.4 at 24 months. Qmax improved from a mean baseline of 7.8 ml/s up to 19.7 ml/s at 12 months. BPHII improved from a baseline of 7.3 to 2.3 at 12 months and further improving to 1.8 at 24 months. IIEF and MSHQ showed no significant change from baseline to 24 months. 11 (6.3%) patients noted retrograde/anejaculation and 8 (4.6%) patients needed retreatment at an average follow-up of 18±10.6 months. CONCLUSIONS: Rezūm therapy is a safe, effective, quick, outpatient procedure in prostate glands ≥80 ml with similar outcomes to prostates <80 mL. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e431 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Roseanne Ferreira More articles by this author Naeem Bhojani More articles by this author Bilal Chughtai More articles by this author Kevin C. Zorn More articles by this author Dean Elterman More articles by this author Expand All Advertisement PDF downloadLoading ...